文 ｜ 胡香赟 编辑 ｜ 海若镜 累 计已服务 70多家药企及科研机构类客户，涉及国内外管线超过100个。 封面来源 ｜ 企业官网 36氪获悉，唯可生物近期已完成近亿元A轮融资。本轮融资由深创投领投，锡创投跟投，募集资金主要用于加速推进细胞和基因 治疗（CGT）美国安评检测中心搭建、CGT安评服务、CGT临床服务和生物育种服务的海外业务拓展等工作。丰和资本任独家财 务顾问。 唯可生物专注于为细胞与基因治疗（CGT）药物提供基于安全性评价的CRO服务，核心团队均来自于德国海德堡大学和德国国家 癌症研究中心，在CGT安评领域拥有多年从业经历，曾协助诺华的CAR-T药物Kymriah、BioMarin的血友病药物Roctavian等多款 基因治疗产品获批上市。 "2021年左右，随着国内CGT领域逐步发展、CAR-T疗法等代表性产品相继上市，监管部门对这类产品的安全性检测工作也愈发 重视。在此背景下，我们与德国GENEWERK团队合作将相关检测技术引进、升级，创办了唯可生物。"唯可生物创始人吴宁表 示。 据了解，现阶段，唯可生物可以为CGT药物提供从药物早期临床研发，CMC开发，到后期IIT临床和注册临床试验、长时 ...

Core Viewpoint - He Yuan Biotechnology (Shanghai) Co., Ltd. reported a revenue of 120 million yuan in the first half of 2025, marking a year-on-year growth of 6.01%, and a non-net loss of 105 million yuan, indicating a reduction in losses compared to the previous year [1] Group 1: Financial Performance - The company achieved a revenue of 120 million yuan in the first half of 2025, reflecting a 6.01% increase year-on-year [1] - The non-net loss was 105 million yuan, which is a reduction of 14.89 million yuan compared to the previous year [1] - The CRO business generated revenue of approximately 40.7 million yuan, a year-on-year increase of 3.79%, while the CDMO business revenue was about 65.6 million yuan, remaining stable compared to the same period last year [1] Group 2: Market and Business Development - The CGT market's activity increased in the first half of 2025, providing growth opportunities for CRO/CDMO companies, although rapid revenue growth is still expected to take time [1] - The CDMO new orders exceeded 90 million yuan in the first half of 2025, with revenue recognition contingent upon the delivery of technical service results and client confirmation [1] - The company is optimistic about the recovery of the CDMO market demand and believes that the increase in downstream customer orders will gradually improve production capacity utilization [1] Group 3: R&D and New Business Directions - R&D investment amounted to approximately 23.2 million yuan, accounting for 19.37% of total revenue, with 2 new invention patent applications and 8 utility model patent applications filed [2] - Revenue from regenerative medicine services, biological reagent testing, and other main businesses reached about 13.4 million yuan, showing a significant year-on-year growth of 61.17%, contributing to the reduction in losses [2] - The company is exploring new business models in regenerative medicine, including partnerships with research institutions and participation in industry standard formulation [2]